# Sanofi's $180M Bet: Kill Every B Cell to End Autoimmune Relapse - Date: 2026-03-23 - Category: Biotech & Life Sciences Sanofi Bets $180M on a San Mateo Startup's Plan to Reset the Immune System Sanofi has licensed worldwide exclusive rights to KT501, a first-in-class trispecific T-cell engager developed by Kali Therapeutics, a small San Mateo startup that dosed its [first patient](https://www.prnewswire.com/news... ---